Effectiveness of cognitive remediation in schizophrenia

Phase 3

• Conditions: Condition 1: Schizoaffective Disorder. Condition 2: Schizophrenia.; Schizoaffective disorder; Schizophrenia

• Registration Number: IRCT2016011810782N2
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

Patients with DSM-IV schizophrenia or schizoaffective disorder, aged 18 to 55 years and with education not less than 3rd grade in guidance school. Patients will be clinically stable and not acutely psychotic (Clinical Global Impression scale score less than 4, and Positive and Negative Syndrome Scale score less than 50). The dosage and the type of antipsychotic medications patients will receive at least during the three weeks prior to the study will be unchanged. At least 12 hours before the intervention, patients will receive their last dose of a benzodiazepine (if any) but no antihistamine medication will be administered.
Exclusion criteria:
Receiving electroconvulsive therapy (ECT) within six weeks prior to the study, mental retardation, uncorrected visual impairment, concurrent consumption of substances with the exception of nicotine and caffeine, a history of head trauma followed by loss of consciousness, suffering from a major neurological disorder (including epilepsy, Parkinson’s disease, dementia, multiple sclerosis, or any motor disability), severe worsening of illness during study requiring a change in medical treatments.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Executive function. Timepoint: Before and after the intervention. Method of measurement: CANTAB Battery.;Attention. Timepoint: Before and after the intervention. Method of measurement: CANTAB Battery.;Memory. Timepoint: Before and after the intervention. Method of measurement: CANTAB Battery.

Secondary Outcome Measures

Name	Time	Method
Global Function. Timepoint: Before and after the intervention. Method of measurement: Global Assessment of Functioning.;Quality of life. Timepoint: Before and after the intervention. Method of measurement: Quality of life questionnaire.;Severity of illness. Timepoint: Before and after the intervention. Method of measurement: Positive and Negative Syndrome Scale, and Clinical global impression.